Cato Allen Easley 4
4 · VistaGen Therapeutics, Inc. · Filed Jan 9, 2012
Insider Transaction Report
Form 4
Cato Allen Easley
10% Owner
Transactions
- Conversion
Common Stock
2011-12-15$9999.44/sh+11,363$113,623,637→ 28,497 total - Exercise of In-Money
Warrant
2011-12-15$0.88/sh−11,363$9,999→ 28,067 totalExercise: $1.75From: 2008-08-25Exp: 2013-12-31→ Common Stock (1 underlying) - Sale
Warrant
2011-12-15$0.88/sh−6,988$6,149→ 28,067 totalExercise: $1.75From: 2008-08-25Exp: 2013-12-31→ Common Stock (1 underlying) - Exercise of In-Money
Warrant
2011-12-15$1.25/sh+212,166$265,208→ 0 total(indirect: By Cato Holding Company)Exercise: $2.50From: 2011-04-29Exp: 2014-05-11→ Common Stock (1 underlying) - Exercise of In-Money
Warrant
2011-12-15$1.05/sh+2,916$3,062→ 0 total(indirect: By Cato Holding Company)Exercise: $2.10From: 2008-03-21Exp: 2013-03-21→ Common Stock (1 underlying) - Exercise of In-Money
Warrant
2011-12-15$0.88/sh−46,542$40,957→ 0 total(indirect: By Cato Holding Company)Exercise: $1.75From: 2008-08-25Exp: 2013-12-31→ Common Stock (1 underlying) - Exercise of In-Money
Warrant
2011-12-15$1.00/sh−162,500$162,500→ 0 total(indirect: By Cato Holding Company)Exercise: $2.00From: 2010-11-19Exp: 2012-08-18→ Common Stock (1 underlying)
Holdings
- 2,916
Option
Exercise: $2.10From: 2008-03-21Exp: 2018-03-21→ Common Stock (1 underlying) - 424,124(indirect: by Cato Holding Company)
Common Stock
Footnotes (2)
- [F1]The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
- [F2]The reporting person is the majority stockholder and chief executive office of Cato Holding Company.